Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain

Published 2011 View Full Article

Authors

Keywords

Journal

LUNG CANCER

Volume 74, Issue 3, Pages 529-534

Publisher

Elsevier BV

Online

2011-05-22

DOI

10.1016/j.lungcan.2011.04.010

Ask authors/readers for more resources

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

LUNG CANCER

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Publish scientific posters with Peeref

Become a Peeref-certified reviewer